Literature DB >> 577111

Respiratory and cardiovascular effects of 3-methylxanthine, a metabolite of theophylline.

C G Persson, K E Andersson.   

Abstract

The effects of 3-methylxanthine (3-MX), a major metabolite of theophylline in man, were studied and compared with those of theophylline in isolated preparations of human and guinea-pig airways, isolated guinea-pig hearts, and in anaesthetized cats. 3-MX was pharmacologically active, producing effects similar to those of theophylline. The guinea-pig and human airways preparations were relaxed; the rate and force of contraction of guinea-pig hearts were increased. In anaesthetized cats, 3-MX decreased the respiratory overflow and arterial blood pressure, and increased the heart rate. Theophylline was always more potent (between 1 and 5 times) than 3-MX. It is suggested that 3-MX may contribute to the effects of theophylline during long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 577111

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  5 in total

Review 1.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

2.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Pharmacokinetics of theophylline and its metabolites during acute renal failure. A case report.

Authors:  T E Leakey; A C Elias-Jones; P E Coates; K J Smith
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

4.  Nonlinear renal excretion of theophylline and its metabolites, 1-methyluric acid and 1,3-dimethyluric acid, in rats.

Authors:  H J Kuh; C K Shim
Journal:  Arch Pharm Res       Date:  1994-04       Impact factor: 4.946

Review 5.  Hypoxia, arterial pH and theophylline disposition.

Authors:  M Richer; Y W Lam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.